Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats With Type 2 Diabetes

Risk of Incident Alzheimer's Disease in Diabetic Patients: A Systematic Review of Prospective Trials

(2017) Daniel Kopf et al.   JOURNAL OF ALZHEIMERS DISEASE

The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease

(2014) Christian Hölscher   Alzheimers & Dementia

Tau protein kinases: Involvement in Alzheimer's disease

(2012) Ludovic Martin et al.   AGEING RESEARCH REVIEWS

The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

(2012) Roger S. McIntyre et al.   BEHAVIOURAL BRAIN RESEARCH

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease

(2012) Suzanne M. de la Monte   Current Alzheimer Research

The development of effective biomarkers for Alzheimer's disease: a review

(2012) Mark S. Henry et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

(2012) Chong Gao et al.   REVIEWS IN THE NEUROSCIENCES

Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus

(2011) R. Keith Campbell   CLINICAL THERAPEUTICS

Current and Emerging Drug Treatment Options for Alzheimerʼs Disease

(2011) Nathan Herrmann et al.   DRUGS

A Common Pathogenic Mechanism Linking Type-2 Diabetes and Alzheimer's Disease: Evidence from Animal Models

(2011) Sun Ah Park   Journal of Clinical Neurology

Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes

(2011) Ying Liu et al.   JOURNAL OF PATHOLOGY

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

(2011) Jonas B. Møller et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Targeting Tau Protein in Alzheimerʼs Disease

(2010) Cheng-Xin Gong et al.   DRUGS & AGING

Phosphatidylinositol 3-Kinase (PI3K) Signaling via Glycogen Synthase Kinase-3 (Gsk-3) Regulates DNA Methylation of Imprinted Loci

(2010) Anthony P. Popkie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glucagon Like Peptide-1-Directed Human Embryonic Stem Cells Differentiation Into Insulin-Producing Cells Via Hedgehog, cAMP, and PI3K Pathways

(2010) Hongxiang Hui et al.   PANCREAS

Linking type 2 diabetes and Alzheimer's disease

(2010) W. Han et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

(2009) Talib Abbas et al.   BEHAVIOURAL BRAIN RESEARCH

Brain glucose transporters,O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease

(2009) Ying Liu et al.   JOURNAL OF NEUROCHEMISTRY

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

(2008) Diana L. Williams et al.   ENDOCRINOLOGY

Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin

(2008) C.G. Jolivalt et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

(2008) Aileen M. Moloney et al.   NEUROBIOLOGY OF AGING